Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Smoldering Multiple Myeloma”

44 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 44 results

Early research (Phase 1)Looking for participantsNCT05055063
What this trial is testing

With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03236428
What this trial is testing

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Who this might be right for
Monoclonal GammopathySmoldering Multiple Myeloma
Dana-Farber Cancer Institute 42
Testing effectiveness (Phase 2)Looking for participantsNCT05469893
What this trial is testing

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
High-risk Smoldering Multiple MyelomaSmoldering Multiple MyelomaMultiple Myeloma
Irene Ghobrial, MD 52
Early research (Phase 1)Study completedNCT02697383
What this trial is testing

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Who this might be right for
Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT02415413
What this trial is testing

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
PETHEMA Foundation 90
Large-scale testing (Phase 3)Study completedNCT00480363
What this trial is testing

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04933539
What this trial is testing

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Looking for participantsNCT05597345
What this trial is testing

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
University of Rochester 15
Testing effectiveness (Phase 2)Ended earlyNCT02943473
What this trial is testing

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Who this might be right for
High Risk Smoldering Multiple Myeloma
Icahn School of Medicine at Mount Sinai 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT03289299
What this trial is testing

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Who this might be right for
Smoldering Multiple Myeloma
International Myeloma Foundation 87
Large-scale testing (Phase 3)Active Not RecruitingNCT04270409
What this trial is testing

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
Sanofi 337
Not applicableLooking for participantsNCT06212323
What this trial is testing

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Who this might be right for
Smoldering Multiple Myeloma
University of Utah 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05014646
What this trial is testing

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Who this might be right for
Smoldering Plasma Cell Myeloma
City of Hope Medical Center 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT04775550
What this trial is testing

DARA RVD For High Risk SMM

Who this might be right for
High-risk Smoldering Multiple MyelomaMultiple Myeloma
Omar Nadeem, MD 61
Testing effectiveness (Phase 2)Study completedNCT01441973
What this trial is testing

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Bristol-Myers Squibb 41
Testing effectiveness (Phase 2)WithdrawnNCT01660997
What this trial is testing

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI)
Not applicableNot Yet RecruitingNCT06745687
What this trial is testing

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Who this might be right for
High Risk Smoldering Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Looking for participantsNCT04776395
What this trial is testing

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Plasma Cell Myeloma
Emory University 68
Testing effectiveness (Phase 2)Study completedNCT01484275
What this trial is testing

Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Who this might be right for
High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC 85
Testing effectiveness (Phase 2)Looking for participantsNCT06100237
What this trial is testing

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Who this might be right for
Multiple Myeloma
Carl Ola Landgren, MD, PhD 50
Load More Results